In June 2023 our group received a 100 000 NOK grant from the ‘Astri og Birger Torsteds legat‘ foundation in Norway.
Our intention is to allocate these funds towards a project centered around the advancement of personalized CRISPR-Cas9 gene editing techniques for CD34+ hematopoietic stem cells (HSC) derived from healthy human donors.
The primary objective is to refine the xenotransplantation procedure for edited CD34+ HSCs in immunodeficient mouse models, specifically NSG mice.
The process aims to assess the safety and effectiveness of the therapy, and gauging the extent of human engraftment within the mouse subjects.
Featured image credit: Oda Hveem (Visuello.)